Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.
The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.
FDA Approves 3 Treatments, Cancer Vaccine Shows Promise
December 20th 2023The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Listen
FDA Approves Opdivo Plus Chemo for Unresectable or Metastatic Bladder Cancer
March 7th 2024The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.
Read More